Our client studies the molecular changes that occur when reflux damages the tissues of the esophagus and upper airway. With a Ph.D. in medical biochemistry from Ege University, she developed her expertise through research on inflammatory pathways and the integrity of the esophageal lining. She later joined the Medical College of Wisconsin as a postdoctoral researcher, extending her work to the role of pepsin in reflux-related injury and its potential as a diagnostic marker and therapeutic target.
Our firm built the petition around the connection between her laboratory findings and specific diagnostic and treatment challenges. We presented her research experience, 17 peer-reviewed publications, and studies examining inflammation and tissue recovery in reflux disease. Her proposed endeavor focused on validating pepsin-based testing, investigating mechanisms associated with disease progression, and evaluating therapies designed to inhibit pepsin-mediated damage. These objectives provided a defined research direction supported by her ongoing work in a US laboratory.
A distinctive strength of this case was the connection between identifying disease and investigating how to interrupt it. Her research approaches pepsin both as a measurable indicator of reflux and as a potential target for treatment, linking biomarker development with therapeutic investigation. USCIS approved her I-140 petition under the EB-2 National Interest Waiver category. Her continuing research seeks to translate that connection into better options for patients whose reflux-related symptoms remain unresolved.
